ClinicalTrials.gg
DrugRead study by study

Dupilumab clinical trials

Also written Dupixent, REGN668 and SAR231893.

studies test it
180
open now
36
in phase 3
46
first study started
2009
ClinicalTrials.gov finds 312 studies for dupilumab. How that becomes 180 here

Every study that search finds has been read, to see whether and how it gives dupilumab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 312Found by its intervention search · See all 312 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 258 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −10
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. +1Give it under a name that search misses: a biosimilar’s code or a misspelling
  4. 303Give dupilumab to participants
  5. −90Observe patients on it, or give it outside a trial
  6. −1Use it as a tool: an imaging tracer or a test of drug response
  7. −26Compare another treatment with it
  8. −6Give it beside what is tested
  9. 180Test it: the count on this site

Get an email when these change. Save the dupilumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Mar 2017 · DUPIXENT · BLA 761055 (FDA, Drugs@FDA)
European Union
26 Sept 2017 · Dupixent · EMEA/H/C/004390 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Dupilumab
124
Dupilumab SAR231893
13
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
4
Dupilumab (SAR231893)
4
Dupilumab SAR231893 (REGN668)
3

Brand

Dupixent
89

Development codes

REGN668
44
SAR231893
43

Studies by the year they started

180 studies that test it; most in 2020 (25)

Studies that test dupilumab, by start year
YearStudies
20091
20101
20113
20124
20135
20146
20158
20164
20176
201815
201910
202025
202121
202213
202321
202419
202510
20268

By phase

A phase 1/2 study counts in both.

Early Phase 1
5
Phase 1
16
Phase 2
57
Phase 3
46
Phase 4
59
No phase
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 93 · Other 87

Sanofi (52) · Regeneron Pharmaceuticals (40) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Icahn School of Medicine at Mount Sinai (5) · Brigham and Women's Hospital (3) · Rigshospitalet, Denmark (3) · University of Michigan (3) · Mayo Clinic (3)

Often tested with

Tested in the same studies.

Omalizumab (3) · Cemiplimab (3) · Itepekimab (2) · Mepolizumab (1) · Triamcinolone Acetonide (1) · Triamcinolone (1) · Hydrocortisone (1) · Grazax (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 8 phase 3 studies under way

Dupilumab is the comparator. A study of two new drugs counts under both.

  • 2Upadacitinib · AbbVie · next primary completion Nov 2026
  • 1Remibrutinib · Novartis Pharmaceuticals · next primary completion Feb 2027
  • 1Tilrekimig · Pfizer · next primary completion Sep 2028
  • 1GS 101 · Jiangsu Genscend Biopharmaceutical Co., Ltd · next primary completion Apr 2027
New treatments tested with it · 1 most studied

New when their studies opened, with dupilumab beside them; studies of each.

Reaching primary completion within a year · 19, 3 in phase 3

Studies that test dupilumab, phase 3 first.

Studies

Open first, then newest update. How each study uses dupilumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 180

See all 180 studies that test dupilumab →

Behind its US label · 23 — the studies the FDA label of DUPIXENT describes

From the Clinical Studies section of DUPIXENT (2026-04), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 118 — no other medicine in its arm

Showing 20 of 118. See all 118 →

Tested with established drugs · 35 — they are given beside it

Showing 20 of 35. See all 35 →

Tested in a combination · 27 — another drug in the study is under test too

Showing 20 of 27. See all 27 →

Beside an established treatment under test · 3 — an approved drug, surgery or radiation is what the study tests

Tested with dupilumab: apremilast 1 · tofacitinib 1

Beside a new treatment under test · 1 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with dupilumab: linvoseltamab 1

Beside supportive care · 2 — a supportive treatment or test is studied
As the comparator · 26 — what is tested is compared with dupilumab

Showing 20 of 26. See all 26 →

Observed · 90 — patients on it are followed, or it is given outside a trial

Showing 20 of 90. See all 90 →

As a tool · 1 — an imaging tracer or a test of drug response

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call dupilumab · ClinicalTrials.gg INT006309

  • MeSH (NLM) C582203dupilumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 420K487FSGDUPILUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1876376Confirmed FDA, Wikidata
  • Wikidata Q5315925dupilumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C162455DupilumabOne source FDA
  • DrugBank DB12159One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion